STOP-HER2: Stopping Trastuzumab in HER2+ MBC (NCT05721248)
The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- Cessation of anti-HER2 treatment (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Mayo Clinic Hospital Arizona — Phoenix, Arizona
- Georgetown University Medical Center — Washington D.C., District of Columbia
- Mayo Clinical Hospital Florida — Jacksonville, Florida
- Dana-Farber Cancer Insitute — Boston, Massachusetts
- DFCI @ Foxborough — Foxborough, Massachusetts
- DFCI @ Merrimack Valley — Methuen, Massachusetts
- DFCI @ Milford Regional Hospital — Milford, Massachusetts
- DFCI @ South Shore Hospital — South Weymouth, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- Duke University — Durham, North Carolina
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Baylor College of Medicine — Houston, Texas
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.